INTRODUCTION: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. METHODS: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. RESULTS: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. CONCLUSIONS: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.
INTRODUCTION:CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. METHODS: 13 malignant melanomapatients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancerpatients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. RESULTS: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanomapatients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostatepatients developed grade 3 and grade 4 neutropenia, respectively. CONCLUSIONS:CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.
Authors: W R Waud; W R Leopold; W L Elliott; D J Dykes; W R Laster; C G Temple; S D Harrison; D P Griswold Journal: Cancer Res Date: 1990-06-01 Impact factor: 12.701
Authors: S R Patel; M A Burgess; N E Papadopolous; G Sidhu; R Gray; C Plager; J Jenkins; R S Benjamin Journal: Invest New Drugs Date: 1998 Impact factor: 3.850
Authors: C de Ines; D Leynadier; I Barasoain; V Peyrot; P Garcia; C Briand; G A Rener; C Temple Journal: Cancer Res Date: 1994-01-01 Impact factor: 12.701
Authors: E K Rowinsky; G S Long; D A Noe; L B Grochow; M K Bowling; S E Sartorius; R C Donehower Journal: Clin Cancer Res Date: 1997-03 Impact factor: 12.531
Authors: A P Kudelka; A Hasenburg; C F Verschraegen; C L Edwards; C A Meyers; D Varma; R S Freedman; A Forman; C A Conrad; W Grove; A Grothey; J J Kavanagh Journal: Anticancer Drugs Date: 1998-06 Impact factor: 2.248